Aarti Drugs Gears Up for Q3 Reveal on 3rd February; Check Key Expectations Here

Posted by : sachet | Mon Feb 02 2026

Click and Sign Up to Get Live Updates on Q3 Results

Aarti Drugs’s Q3 results FY26 are scheduled to be announced on 3rd February 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.

Table of Contents

Aarti Drugs Q3 Results 2026 Preview

Aarti Drugs’ revenue is expected to be in the range of ₹556.60 crore, a 6.97% YoY increase.
Profit After Tax, or PAT, is projected to fall by 6.97% YoY.
Net profit is ₹37.04 crore, a rise 5.82% YoY
EBITDA to fall 6.97%

Aarti Drugs Share Performance

Over the past six months, Aarti Drugs’ share price has fallen by 23.34% to ₹378.00.
Moreover, over the past year, the stock has decreased by 10.72%.
Despite this weak short-term performance, Aarti Drugs’ stock has delivered a financially sound 44.19% return over the past 5 years.
As of 2nd February 2026, the stock traded at ₹378.00 per share.

About Aarti Drugs

Aarti Drugs is engaged in manufacturing and selling of pharmaceutical ingredients, supplying high-quality drug ingredients (like metformin, metronidazole, ketoconazole, etc.) to domestic and global pharmaceutical companies with compliance to international standards.

Key Factors to Watch for Aarti Drugs Q3 Results FY26

Growth in Revenue: To watch the performance of the sales volume and revenue on the basis of last year and the previous quarter. A strong indication of growth is a positive signal.
Profitability & Margins: EBITDA & PAT margins are important as they show the impact of the control and pricing power.
Product mix & Market Demand: It is important to watch the key products and segments where there is a strong demand for the company’s product segments
Raw material cost & Input prices: Price movements in raw materials are highly important, as a slight increase in the cost of chemicals and APIs directly impacts margins. The major focus in this quarter is on managing inflation.
Export & Domestic sales trend: Company growth is highly dependent on the domestic demand and exports.

Final Thoughts

Aarti Drugs will announce its Q3 FY26 results on 2nd February 2026. Analysts expect 6.97% YoY revenue growth, a 5.82% fall in PAT, and a 10.11% rise in EBITDA. Aarti Drugs focuses on manufacturing and exporting APIs, pharmaceutical intermediates, and speciality chemicals, backed by strong R&D and global regulatory compliance.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!